Curdin Conrad

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


126 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
Sous presse
 
ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis.
Cerminara S.E., Cvijetic I., Huber S., Müller S., Kostner L., Goessinger E.V., Narainsing J., Dutilh G., Heidemeyer K., Yawalkar N. et al. Journal of the European Academy of Dermatology and Venereology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2627DC6163D3]
 
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis.
Fossati C., Guenova E., Conrad C., Gilliet M., Seremet T. Journal of the European Academy of Dermatology and Venereology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EFC6FDA7CFE4]
2024
 
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases.
Seremet T., Di Domizio J., Girardin A., Yatim A., Jenelten R., Messina F., Saidoune F., Schlapbach C., Bogiatzi S., Minisini F. et al., 2024/12/18. Nature communications, 15 (1) p. 10688. Peer-reviewed.
[DOI][Pmid][serval:BIB_EE04B0E74C9B]
 
A European Roundtable "Addressing Under-Prioritized Skin Diseases: Policy Responses to High-Burden Conditions".
Mammadov Y., Austin J., Shipowick T., Veldman K., Eming S., Szegedi A., Sprecher E., Conrad C., 2024/12. The Journal of investigative dermatology, 144 (12) pp. 2631-2633. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_626E383E3A1F]
 
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
Chiricozzi A., Coscarella G., Puig L., Vender R., Yeung J., Carrascosa J.M., Piaserico S., Gisondi P., Lynde C., Ferreira P. et al., 2024/11. Journal of the European Academy of Dermatology and Venereology, 38 (11) pp. 2175-2185. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3E85C936E7FE]
 
Predictors of initiating biologics in the treatment of psoriasis.
Linnemann E., Nielsen M.L., Maul L.V., Richter C., Dommann I., Zink A., Schlapbach C., Yawalkar N., Conrad C., Cozzio A. et al., 2024/10. International journal of dermatology, 63 (10) pp. e231-e239. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6385660DD65E]
 
Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis.
Blauvelt A., Conrad C., Noe M.H., 2024/09/01. JAMA dermatology, 160 (9) pp. 919-920. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AE61778D518B]
 
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
Puig L., Costanzo A., de Jong EMGJ, Torres T., Warren R.B., Wapenaar R., Wegner S., Gorecki P., Gramiccia T., Jazra M. et al., 2024/09. Dermatology and therapy, 14 (9) pp. 2539-2558. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6662A036C71F]
Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network.
Wolf P., Ceovic R., Conrad C., Falkensteiner K., Graier T., Kołt-Kamińska M., Marovt M., Mateeva V., Maul J.T., Navarini A.A. et al., 2024/08. Journal of the European Academy of Dermatology and Venereology, 38 (8) pp. 1531-1542. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0FFDB4FEF9D6]
 
Targeting IL-1 controls refractory pityriasis rubra pilaris.
Schmauch E., Severin Y., Xing X., Mangold A., Conrad C., Johannsen P., Kahlenberg J.M., Mellett M., Navarini A., Nobbe S. et al., 2024/07/05. Science advances, 10 (27) pp. eado2365. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C2D3F8232AED]
Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26.
Baldo A., Di Domizio J., Yatim A., Vandenberghe-Dürr S., Jenelten R., Fries A., Grizzetti L., Kuonen F., Paul C., Modlin R.L. et al., 2024/05/06. The Journal of experimental medicine, 221 (5). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F6D0EEF91DAC]
An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis.
Eyerich K., Krueger J., Stahle M., Schakel K., Conrad C., Armstrong A., Gniadecki R., Puig L., Scoble T., Williams N., 2024/05. Journal of the European Academy of Dermatology and Venereology, 38 (5) pp. e424-e427. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_250494FB338A]
 
Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study.
Nielsen M.L., Petersen T.C., Maul L.V., Thyssen J.P., Thomsen S.F., Wu J.J., Navarini A.A., Kündig T., Yawalkar N., Schlapbach C. et al., 2024/04. Journal of psoriasis and psoriatic arthritis, 9 (2) pp. 41-50. Peer-reviewed.
[DOI][Pmid][serval:BIB_C055CD3EF40D]
 
Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT).
Verardi F., Maul L.V., Borsky K., Steinmann S., Rosset N., Pons H.O., Sorbe C., Yawalkar N., Micheroli R., Egeberg A. et al., 2024/04. Journal of the European Academy of Dermatology and Venereology, 38 (4) pp. 719-731. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A5BFB7D5A3CD]
 
Thérapie du psoriasis pédiatrique : présent et futur [Treatment of childhood psoriasis: present and future]
Messina F., Conrad C., Morren M.A., 2024/03/27. Revue medicale suisse, 20 (867) pp. 631-635. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D7E8B3C848A3]
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L., Costanzo A., de Jong EMGJ, Torres T., Warren R.B., Wapenaar R., Wegner S., Gorecki P., Gramiccia T., Jazra M. et al., 2024/03. American journal of clinical dermatology, 25 (2) pp. 315-325. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ED60BAACD034]
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
Egeberg A., Conrad C., Gorecki P., Wegner S., Buyze J., Acciarri L., Thaçi D., 2024/03. Dermatology and therapy, 14 (3) pp. 745-758. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3774E7C2AE70]
Freedom from disease in plaque psoriasis: Comparing the perceived importance of voting round 2 statements from a Delphi consensus of patients, physicians and nurses.
van Ee I., Deprez E., Egeberg A., Conrad C., Corazza V., Donati L., Lambert J., Lăpădatu R., Meyer A., Paul C. et al., 2024/01. Journal of the European Academy of Dermatology and Venereology, 38 (1) pp. e16-e19. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3AEA392299CF]
 
Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis.
Conrad C., Schlapbach C., 2024/01. The Journal of allergy and clinical immunology, 153 (1) pp. 93-94. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4054C394C639]
2023
Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2.
Armstrong A., Eyerich K., Conrad C., Zhu Y., Yang Y.W., Miller M., You Y., Shen Y.K., Foley P., Griffiths CEM et al., 2023/12. Journal of the European Academy of Dermatology and Venereology, 37 (12) pp. e1375-e1379. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ECDD80B202C8]
 
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra S.G., Yosipovitch G., Legat F.J., Reich A., Paul C., Simon D., Naldi L., Lynde C., De Bruin-Weller M.S., Nahm W.K. et al., 2023/10/26. The New England journal of medicine, 389 (17) pp. 1579-1589. Peer-reviewed.
[DOI][Pmid][serval:BIB_0A637DD42145]
Differentiation of IL-26+ TH17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis.
Fries A., Saidoune F., Kuonen F., Dupanloup I., Fournier N., Guerra de Souza A.C., Haniffa M., Ma F., Gudjonsson J.E., Roesner L. et al., 2023/06/30. Nature communications, 14 (1) p. 3878. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F7440A1D7F03]
A severe case of neuroleukemiosis caused by B cell chronic lymphocytic leukemia, presenting as mononeuritis multiplex.
Vicino A., Cochet S., Pistocchi S., Conrad C., Ribi C., Du Pasquier R., Brouland J.P., Théaudin M., 2023/06. Journal of the peripheral nervous system, 28 (2) pp. 266-268. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A5312D01C4F]
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Iversen L., Conrad C., Eidsmo L., Costanzo A., Narbutt J., Pinter A., Kingo K., Rivera Diaz R., Kolbinger F., Nanna M. et al., 2023/05. Journal of the European Academy of Dermatology and Venereology, 37 (5) pp. 1004-1016. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F44282E5D35A]
A plain language summary of what freedom from disease means to people with psoriasis according to doctors, nurses, and people with psoriasis.
Ee I.V., Deprez E., Egeberg A., Conrad C., Corazza V., Donati L., Lambert J., Lăpădatu R., Meyer A., Paul C. et al., 2023/04. Journal of comparative effectiveness research, 12 (4) pp. e220206. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AEF9C795915D]
Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea.
Mylonas A., Hawerkamp H.C., Wang Y., Chen J., Messina F., Demaria O., Meller S., Homey B., Di Domizio J., Mazzolai L. et al., 2023/02/22. JCI insight, 8 (4) pp. e151846. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5858E94898BB]
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U., Barker J., Conrad C., Jullien D., Gisondi P., Flower A., Reddy J., Paris M., Picard H., Jardon S. et al., 2023/02. Journal of the European Academy of Dermatology and Venereology, 37 (2) pp. 348-355. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_648946B8915D]
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D., Vender R., de Rie M.A., Conrad C., Pariser D.M., Strober B., Vanvoorden V., Wang M., Madden C., de Cuyper D. et al., 2023/01/23. The British journal of dermatology, 188 (1) pp. 22-31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4984B95B8B7E]
 
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study.
Chiricozzi A., Ferrucci S.M., Di Nardo L., Gori N., Balato A., Ortoncelli M., Maurelli M., Galluzzo M., Munera Campos M., Seremet T. et al., 2023. Expert opinion on biological therapy, 23 (12) pp. 1307-1315. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5C65215DEC5B]
2022
Une simple éruption cutanée?
Thorens Aline, Kokkinakis Ioannis, Bogiatzi Sofia, Favrat Bernard, Conrad Curdin, Seremet Teofila, 2022/11/23. Forum Médical Suisse ‒ Swiss Medical Forum, 22 (47). Peer-reviewed.
[URN][DOI][serval:BIB_2FD790560789]
 
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T., Puig L., Vender R., Yeung J., Carrascosa J.M., Piaserico S., Gisondi P., Lynde C., Ferreira P., Bastos P.M. et al., 2022/11. American journal of clinical dermatology, 23 (6) pp. 891-904. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8BD57CEC2813]
Inhibiteurs des Janus kinases : nouvelles perspectives pour la médecine de précision ? [Janus kinase inhibitors : new perspectives for precision medicine ?]
Tachet J., Dumusc A., Conrad C., Grandoni F., Chalandon Y., Ribi C., Buclin T., Girardin F., 2022/10/19. Revue medicale suisse, 18 (800) pp. 1979-1983. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0D12F79D0C49]
Biomarkers of disease progression in people with psoriasis: a scoping review.
Ramessur R., Corbett M., Marshall D., Acencio M.L., Barbosa I.A., Dand N., Di Meglio P., Haddad S., Jensen AHM, Koopmann W. et al., 2022/10. The British journal of dermatology, 187 (4) pp. 481-493. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F30819CCD63D]
Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
Corbett M., Ramessur R., Marshall D., Acencio M.L., Ostaszewski M., Barbosa I.A., Dand N., Di Meglio P., Haddad S., Jensen AHM et al., 2022/10. The British journal of dermatology, 187 (4) pp. 494-506. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF0562FE3E3D]
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M., Sator P.G., von Kiedrowski R., Conrad C., Rigopoulos D., Romanelli M., Ghislain P.D., Torres T., Ioannides D., Aassi M. et al., 2022/10. Journal of the European Academy of Dermatology and Venereology, 36 (10) pp. 1796-1804. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C9B923938980]
Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort.
Assan F., Husson B., Hegazy S., Seneschal J., Aubin F., Mahé E., Jullien D., Sbidian E., D'Incan M., Conrad C. et al., 2022/09. Journal of the European Academy of Dermatology and Venereology, 36 (9) pp. 1578-1583. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1F752DFF9A44]
Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021-a two-round Delphi survey among international experts.
Ziehfreund S., Tizek L., Hangel N., Fritzsche M.C., Weidinger S., Smith C., Bryce P.J., Greco D., van den Bogaard E.H., Flohr C. et al., 2022/09. Journal of the European Academy of Dermatology and Venereology, 36 (9) pp. 1467-1476. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DE72A9DCD046]
 
TYK-ing all the boxes in psoriasis.
Schlapbach C., Conrad C., 2022/06. The Journal of allergy and clinical immunology, 149 (6) pp. 1936-1939. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F9865D08F780]
 
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
van Huizen A.M., Menting S.P., Gyulai R., Iversen L., van der Kraaij G.E., Middelkamp-Hup M.A., Warren R.B., Spuls P.I., SPIN MTX Consensus Survey Study Group, Schejtman A.A. et al., 2022/05/01. JAMA dermatology, 158 (5) pp. 561-572. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B539AD0B6ECF]
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.
Reich K., Conrad C., Kristensen L.E., Smith S.D., Puig L., Rich P., Sapin C., Holzkaemper T., Koppelhus U., Schuster C., 2022/05. The Journal of dermatological treatment, 33 (3) pp. 1652-1660. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03FD28E40BB4]
The biological basis of disease recurrence in psoriasis: a historical perspective and current models.
Puig L., Costanzo A., Muñoz-Elías E.J., Jazra M., Wegner S., Paul C.F., Conrad C., 2022/05. The British journal of dermatology, 186 (5) pp. 773-781. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B5C6A3A10DD]
Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses.
Stalder R., Brembilla N., Conrad C., Yawalkar N., Navarini A., Boehncke W.H., Kaya G., 2022/04. Clinical and experimental dermatology, 47 (4) pp. 675-683. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A648075F44ED]
Eczéma induit par les anti-IL-17 et le yin-yang Th2/Th17 [Anti-IL17 induced eczema and the yin-yang of Th2 and Th17]
Nidegger A., Jenelten R., Conrad C., 2022/03/30. Revue medicale suisse, 18 (775) pp. 574-577. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A467263B846F]
Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians.
van Ee I., Deprez E., Egeberg A., Augustin M., Conrad C., Corazza V., Donati L., Lambert J., Lăpădatu R., Meyer A. et al., 2022/03. Journal of the European Academy of Dermatology and Venereology, 36 (3) pp. 403-412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_73AFCE8CCB66]
Ixekizumab and ustekinumab in psoriasis: post-hoc comparison of onset and duration of treatment response.
Radtke M., Conrad C., Schuster C., Saure D., Mert C., Riedl E., Costanzo A., 2022/03. The Journal of dermatological treatment, 33 (2) pp. 1168-1170. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C9A7B7A0C724]
 
Papillon-Lefevre syndrome treated by acitretin: case report and cytokine profile.
Leuenberger M., Fischer L., Mylonas A., Huber M., Di Domizio J., Gilliet M., Conrad C., Hohl D., 2022/03. Journal of the European Academy of Dermatology and Venereology, 36 (3) pp. e235-e238. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A3461686B46A]
The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.
Domizio J.D., Gulen M.F., Saidoune F., Thacker V.V., Yatim A., Sharma K., Nass T., Guenova E., Schaller M., Conrad C. et al., 2022/03. Nature, 603 (7899) pp. 145-151. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EB150385781D]
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
Conrad C., Ortmann C.E., Vandemeulebroecke M., Kasparek T., Reich K., 2022/01. Dermatology and therapy, 12 (1) pp. 233-241. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A6C8705C68DD]
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
Klein T.M., Blome C., Kleyn C.E., Conrad C., Sator P.G., Ståhle M., Eyerich K., Radtke M.A., Bundy C., Cordey M. et al., 2022/01. Dermatology and therapy, 12 (1) pp. 81-95. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_77EA92840B70]
2021
 
Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H., Choon S.E., Marrakchi S., Burden A.D., Tsai T.F., Morita A., Navarini A.A., Zheng M., Xu J., Turki H. et al., 2021/12/23. The New England journal of medicine, 385 (26) pp. 2431-2440. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3270ED21E706]
 
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
Maul J.T., Augustin M., Sorbe C., Conrad C., Anzengruber F., Mrowietz U., Reich K., French L.E., Radtke M., Häusermann P. et al., 2021/12. The British journal of dermatology, 185 (6) pp. 1160-1168. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3182B041A34]
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
Brunner P.M., Conrad C., Vender R., Grond S., Schuster C., Patel H., Xu W., Carrascosa Carrillo J.M., 2021/10. The British journal of dermatology, 185 (4) pp. 865-867. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65744C0AFDC2]
 
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T., Puig L., Vender R., Lynde C., Piaserico S., Carrascosa J.M., Gisondi P., Daudén E., Conrad C., Mendes-Bastos P. et al., 2021/07. American journal of clinical dermatology, 22 (4) pp. 567-579. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_02D6835FB766]
New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis.
Lande R., Palazzo R., Mennella A., Pietraforte I., Cadar M., Stefanantoni K., Conrad C., Riccieri V., Frasca L., 2021/03/28. Antibodies, 10 (2) p. 12. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A944932E1A0F]
 
Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus.
Lande R., Pietraforte I., Mennella A., Palazzo R., Spinelli F.R., Giannakakis K., Spadaro F., Falchi M., Riccieri V., Stefanantoni K. et al., 2021/02/06. International journal of molecular sciences, 22 (4) p. 1650. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F216A4047EA8]
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
Augustin M., Kleyn C.E., Conrad C., Sator P.G., Ståhle M., Eyerich K., Radtke M.A., Bundy C., Mellars L., Greggio C. et al., 2021/01. Journal of the European Academy of Dermatology and Venereology, 35 (1) pp. 123-134. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_114D6CF8D47F]
 
Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
Maul J.T., Anzengruber F., Conrad C., Cozzio A., Häusermann P., Jalili A., Kolios AGA, Laffitte E., Lapointe A.K., Mainetti C. et al., 2021. Dermatology, 237 (2) pp. 166-178. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_96E62FB35099]
2020
 
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.
Husson B., Barbe C., Hegazy S., Seneschal J., Aubin F., Mahé E., Jullien D., Sbidian E., D'Incan M., Conrad C. et al., 2020/10. Journal of the European Academy of Dermatology and Venereology, 34 (10) pp. 2330-2338. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1E306945EB46]
 
The commensal skin microbiota triggers type I IFN-dependent innate repair responses in injured skin.
Di Domizio J., Belkhodja C., Chenuet P., Fries A., Murray T., Mondéjar P.M., Demaria O., Conrad C., Homey B., Werner S. et al., 2020/09. Nature immunology, 21 (9) pp. 1034-1045. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6FD139272D6D]
 
Baricitinib-induced paradoxical psoriasis.
Di Domizio J., Castagna J., Algros M.P., Prati C., Conrad C., Gilliet M., Wendling D., Aubin F., 2020/08. Journal of the European Academy of Dermatology and Venereology, 34 (8) pp. e391-e393. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88CDDBC93191]
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
Wasel N., Thaçi D., French L.E., Conrad C., Dutronc Y., Gallo G., Berggren L., Lacour J.P., 2020/08. Dermatology and therapy, 10 (4) pp. 663-670. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC5861C35165]
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A., Balato A., Conrad C., Conti A., Dapavo P., Ferreira P., Gaiani F.M., Leite L., Malagoli P., Mendes-Bastos P. et al., 2020/08. The Journal of dermatological treatment, 31 (5) pp. 476-483. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5B2E2BB52978]
 
Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
Lande R., Mennella A., Palazzo R., Pietraforte I., Stefanantoni K., Iannace N., Butera A., Boirivant M., Pica R., Conrad C. et al., 2020/07/19. International journal of molecular sciences, 21 (14) p. 5102. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_565271192042]
Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
Smith S.D., Conrad C., Ramharter M., Gottlieb A.B., Patel H., Xu W., Riedl E., Schuster C., 2020/07. Journal of the American Academy of Dermatology, 83 (1) pp. 261-263. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FB5BC8CC849]
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U., Sfikakis P.P., Gaffney K., Sator P.G., von Kiedrowski R., Bounas A., Gullick N., Conrad C., Rigopoulos D., Lespessailles E. et al., 2020/06. Advances in therapy, 37 (6) pp. 2865-2883. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8AEBAA423F8E]
2019
 
Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry.
Cazzaniga S., Anzengruber F., Augustin M., Boehncke W.H., Borradori L., Conrad C., Cozzio A., Djamei V., French L.E., Gilliet M. et al., 2019/12. Journal of the European Academy of Dermatology and Venereology, 33 (12) pp. 2313-2318. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_27E4D0CA2FC3]
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
Salomé B., Gomez-Cadena A., Loyon R., Suffiotti M., Salvestrini V., Wyss T., Vanoni G., Ruan D.F., Rossi M., Tozzo A. et al., 2019/11/26. Blood advances, 3 (22) pp. 3674-3687. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BC26C680B22]
 
IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation.
Senra L., Mylonas A., Kavanagh R.D., Fallon P.G., Conrad C., Borowczyk-Michalowska J., Wrobel L.J., Kaya G., Yawalkar N., Boehncke W.H. et al., 2019/08. The Journal of investigative dermatology, 139 (8) pp. 1732-1742.e17. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_11FE0D1CC0C6]
 
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
Torres T., Balato A., Conrad C., Conti A., Dapavo P., Ferreira P., Gaiani F., Leite L., Malagoli P., Mendes-Bastos P. et al., 2019/07. Journal of the American Academy of Dermatology, 81 (1) pp. 273-275. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6E8075B62F23]
 
Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice.
Maul J.T., Navarini A.A., Sommer R., Anzengruber F., Sorbe C., Mrowietz U., Drach M., Blome C., Boehncke W.H., Thaci D. et al., 2019/04. Journal of the European Academy of Dermatology and Venereology, 33 (4) pp. 700-708. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_69486A206F03]
 
Psoriasis paradoxal induit par anti-TNF – un challenge en clinique [Paradoxical psoriasis induced by anti-TNF - a clinical challenge]
Nidegger A., Mylonas A., Conrad C., 2019/03/27. Revue medicale suisse, 15 (644) pp. 668-671. Peer-reviewed.
[Pmid][serval:BIB_5AB6A9BE087A]
 
Human "T<sub>H</sub>9" cells are a subpopulation of PPAR-γ<sup>+</sup> T<sub>H</sub>2 cells.
Micossé C., von Meyenn L., Steck O., Kipfer E., Adam C., Simillion C., Seyed Jafari S.M., Olah P., Yawlkar N., Simon D. et al., 2019/01/18. Science immunology, 4 (31). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F1E6E4C16DDC]
2018
Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.
Hartwig T., Zwicky P., Schreiner B., Yawalkar N., Cheng P., Navarini A., Dummer R., Flatz L., Conrad C., Schlapbach C. et al., 2018/12/26. Cell reports, 25 (13) pp. 3564-3572.e4. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_507439CD5CBC]
 
Psoriasis: from Pathogenesis to Targeted Therapies.
Conrad C., Gilliet M., 2018/02. Clinical reviews in allergy & immunology, 54 (1) pp. 102-113. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_54E377C5C063]
TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.
Conrad C., Di Domizio J., Mylonas A., Belkhodja C., Demaria O., Navarini A.A., Lapointe A.K., French L.E., Vernez M., Gilliet M., 2018/01/02. Nature communications, 9 (1) p. 25. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF655037E4F5]
 
Diversification of human plasmacytoid predendritic cells in response to a single stimulus.
Alculumbre S.G., Saint-André V., Di Domizio J., Vargas P., Sirven P., Bost P., Maurin M., Maiuri P., Wery M., Roman M.S. et al., 2018/01. Nature immunology, 19 (1) pp. 63-75. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BDC98A31CFA1]
Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon.
Mylonas A., Conrad C., 2018. Frontiers in immunology, 9 p. 2746. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_57A9835FCAA8]
2017
 
Swiss S1 guideline for the treatment of rosacea.
Anzengruber F., Czernielewski J., Conrad C., Feldmeyer L., Yawalkar N., Häusermann P., Cozzio A., Mainetti C., Goldblum D., Läuchli S. et al., 2017/11. Journal of the European Academy of Dermatology and Venereology, 31 (11) pp. 1775-1791. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DB5AED9B2C00]
Mise au point sur la rectocolite ulcéro-hémorragique en 2017 [Management of ulcerative colitis in 2017]
Moschouri E., Hessler R., Pittet V., Velin D., Conrad C., Hahnloser D., Gié O., Michetti P., Schoepfer A.M., Maillard M.H., 2017/08/30. Revue medicale suisse, 13 (572) pp. 1480-1486. Peer-reviewed.
[URN][Pmid][serval:BIB_F34A824E37CF]
Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
Feldmeyer L., Mylonas A., Demaria O., Mennella A., Yawalkar N., Laffitte E., Hohl D., Gilliet M., Conrad C., 2017/04/01. JAMA dermatology, 153 (4) pp. 304-308. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83DD35FFCF79]
 
Xenotransplantation Model of Psoriasis.
Di Domizio J., Conrad C., Gilliet M., 2017. pp. 83-90 dans Methods in molecular biology chap. 7, Springer.
[DOI][Pmid][serval:BIB_F2F77B001751]
2016
Targeting CD8(+) T cells prevents psoriasis development.
Di Meglio P., Villanova F., Navarini A.A., Mylonas A., Tosi I., Nestle F.O., Conrad C., 2016/07. The Journal of allergy and clinical immunology, 138 (1) pp. 274-276.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_14A789D6773B]
 
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
Maul J.T., Djamei V., Kolios AGA, Meier B., Czernielewski J., Jungo P., Yawalkar N., Mainetti C., Laffitte E., Spehr C. et al., 2016. Dermatology (Basel, Switzerland), 232 (6) pp. 640-647. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5EC0EEF20B28]
 
PASS Syndrome: An IL-1-Driven Autoinflammatory Disease.
Leuenberger M., Berner J., Di Lucca J., Fischer L., Kaparos N., Conrad C., Hohl D., So A., Gilliet M., 2016. Dermatology (Basel, Switzerland), 232 (2) pp. 254-258. Peer-reviewed.
[DOI][Pmid][serval:BIB_911106312079]
 
Rosacée: où en sommes-nous [Rosacea: what's new?].
Czernielewski J., Conrad C., 2016. Revue Medicale Suisse, 12 (512) pp. 646, 648-646, 652.
[Pmid][serval:BIB_88D03413B042]
 
Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
Jungo P., Maul J.T., Djamei V., von Felten S., Kolios AGA, Czernielewsk J., Yawalkar N., Odermatt O., Laffitte E., Anliker M. et al., 2016. Dermatology (Basel, Switzerland), 232 (6) pp. 655-663. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5BB7266E1A3F]
 
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Kolios A.G., Yawalkar N., Anliker M., Boehncke W.H., Borradori L., Conrad C., Gilliet M., Häusermann P., Itin P., Laffitte E. et al., 2016. Dermatology (basel, Switzerland), 232 (4) pp. 385-406. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_83C87FCDF37E]
2015
 
Psoriasis: nouveautés et défis en 2015 [Psoriasis: advances and challenges in 2015]
Conrad C., Triboulet C., Gilliet M., 2015/04/01. Revue medicale suisse, 11 (468) pp. 754,756-758. Peer-reviewed.
[Pmid][serval:BIB_927F76EEA451]
 
Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA.
Lande R., Chamilos G., Ganguly D., Demaria O., Frasca L., Durr S., Conrad C., Schröder J., Gilliet M., 2015. European Journal of Immunology, 45 (1) pp. 203-213. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09903BFB8833]
 
Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.
Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., Chamilos G., Feldmeyer L., Marinari B., Chon S. et al., 2015..
[DOI][WoS][Pmid][serval:BIB_58D050B8460C]
TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26.
Meller S., Di Domizio J., Voo K.S., Friedrich H.C., Chamilos G., Ganguly D., Conrad C., Gregorio J., Le Roy D., Roger T. et al., 2015. Nature Immunology, 16 (9) pp. 970-979. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8915C0704772]
 
The dermatologists' role in managing psoriatic arthritis: results of a swiss delphi exercise intended to improve collaboration with rheumatologists.
Boehncke W.H., Anliker M.D., Conrad C., Dudler J., Hasler F., Hasler P., Häusermann P., Kyburz D., Laffitte E., Michel B.A. et al., 2015. Dermatology, 230 (1) pp. 75-81. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2164E0836C97]
2014
 
Residents’corner June 2014. DeRmpath & Clinic: Dermatopathological features observed in paradoxical psoriasis induced by anti-TNF therapy.
Clayton Helena, Vernez Maxime, Conrad Curdin, 2014/05. European Journal of Dermatology, 24 (3) pp. 422-422.
[DOI][WoS][serval:BIB_427725C59BA5]
Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphoma
Kuonen F., Bucher M., de Leval L., Vernez M., Gilliet M., Conrad C., Feldmeyer L., 2014. Case Reports in Dermatology, 6 (1) pp. 37-42. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A4DCA0AC9D4C]
 
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.
Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., Chamilos G., Feldmeyer L., Marinari B., Chon S. et al., 2014. Nature Communications, 5 p. 5621. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94227173F2D6]
2013
Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison.
Conrad C., Gilliet M., 2013/05. OncoImmunology, 2 (5) pp. e23887.
[URN][DOI][WoS][Pmid][serval:BIB_36ED7FF628CE]
 
Anti-TNF Therapy in the Treatment of Psoriasis in a Patient with Acute-on-Chronic Pancreatitis.
Clayton H., Flatz L., Vollenweider-Roten S., Schoepfer A., Gilliet M., Conrad C., 2013. Dermatology, 227 (3) pp. 193-196.
[DOI][WoS][Pmid][serval:BIB_34D5793D40A3]
Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy
Flatz L., Conrad C., 2013. Psoriasis: Targets and Therapy, 3 pp. 1-10.
[URN][DOI][serval:BIB_6CEDFA839BA0]
 
Zur Krankheitslast von Psoriasis-Patienten in der Schweiz
Kolios A.G.A., Czernielewski J., Häusermann P., Yawalkar N., Navarini A.A., Thurneysen S., Laffitte E., Djamei V., Spehr C., Anliker M. et al., 2013. Dermatologica Helvetica, 25 (10) pp. 28-31.
[serval:BIB_0B3B44682744]
2012
 
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells.
Conrad C., Gregorio J., Wang Y.H., Ito T., Meller S., Hanabuchi S., Anderson S., Atkinson N., Ramirez P.T., Liu Y.J. et al., 2012. Cancer Research, 72 (20) pp. 5240-5249.
[DOI][WoS][Pmid][serval:BIB_7B26C9A25D39]
 
Type I IFNs at the interface between cutaneous immunity and epidermal remodeling.
Conrad C., Gilliet M., 2012. Journal of Investigative Dermatology, 132 (7) pp. 1759-1762.
[DOI][WoS][Pmid][serval:BIB_AEF7D86CB1FD]
2011
 
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.
Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V. et al., 2011. Science Translational Medicine, 3 (73) pp. 73ra19.
[DOI][WoS][Pmid][serval:BIB_675744544AC5]
2010
Estimation of cost-of-illness in patients with psoriasis in Switzerland.
Navarini A.A., Laffitte E., Conrad C., Piffaretti P., Brock E., Ruckdaeschel S., Trüeb R.M., 2010/02/06. Swiss medical weekly, 140 (5-6) pp. 85-91. Peer-reviewed.
[WoS][Pmid][serval:BIB_04EE21053072]
 
Cutting edge: A critical functional role for IL-23 in psoriasis.
Tonel G., Conrad C., Laggner U., Di Meglio P., Grys K., McClanahan T.K., Blumenschein W.M., Qin J.Z., Xin H., Oldham E. et al., 2010. Journal of Immunology, 185 (10) pp. 5688-5691.
[DOI][WoS][Pmid][serval:BIB_2209B1E7AB65]
 
Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons.
Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A., Arai N., Gallo R.L., Digiovanni J., Gilliet M., 2010. Journal of Experimental Medicine, 207 (13) pp. 2921-2930.
[DOI][WoS][Pmid][serval:BIB_5DD07D2A54A6]
 
Trauma as triggering factor for development of melanocytic nevi.
Navarini A.A., Kolm I., Calvo X., Kamarashev J., Kerl K., Conrad C., French L.E., Braun R.P., 2010. Dermatology, 220 (4) pp. 291-296.
[DOI][WoS][Pmid][serval:BIB_0E25E62431A5]
2009
 
Interplay between keratinocytes and immune cells--recent insights into psoriasis pathogenesis.
Tonel G., Conrad C., 2009. International Journal of Biochemistry and Cell Biology, 41 (5) pp. 963-968.
[DOI][WoS][Pmid][serval:BIB_51C2109254B0]
 
Melanoma and innate immunity--aActive inflammation or just erroneous attraction? Melanoma as the source of leukocyte-attracting chemokines.
Navarini-Meury A.A., Conrad C., 2009. Seminars in Cancer Biology, 19 (2) pp. 84-91.
[DOI][WoS][Pmid][serval:BIB_8C228BBB0798]
 
Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids.
Conrad C., Meller S., Gilliet M., 2009. Seminars in Immunology, 21 (3) pp. 101-109.
[DOI][WoS][Pmid][serval:BIB_5488BF5638A3]
2008
 
Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J., Zipser M.C., Conrad C., Oberholzer P.A., Cozzio A., Knuth A., French L.E., Dummer R., 2008. European Journal of Dermatology, 18 (5) pp. 566-570.
[DOI][WoS][Pmid][serval:BIB_780CB7B2F45E]
2007
 
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis.
Conrad C., Boyman O., Tonel G., Tun-Kyi A., Laggner U., de Fougerolles A., Kotelianski V., Gardner H., Nestle F.O., 2007. Nature medicine, 13 (7) pp. 836-842. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1C84D2FE663]
 
The pathogenic role of tissue-resident immune cells in psoriasis.
Boyman O., Conrad C., Tonel G., Gilliet M., Nestle F.O., 2007. Trends in Immunology, 28 (2) pp. 51-57. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6D1DC4431814]
2006
 
Animal models of psoriasis and psoriatic arthritis: an update.
Conrad C., Nestle F.O., 2006. Current Rheumatology Reports, 8 (5) pp. 342-347.
[Pmid][serval:BIB_B51329D79055]
 
Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
Farkas A., Conrad C., Tonel G., Borbenyi Z., Kemeny L., Dobozy A., Nestle F.O., 2006. Skin pharmacology and physiology, 19 (3) pp. 124-131. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D30536D44003]
2005
 
Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis.
Boyman O., Conrad C., Dudli C., Kielhorn E., Nickoloff B.J., Nestle F.O., 2005/06. The British journal of dermatology, 152 (6) pp. 1211-1218. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_31967363D913]
 
Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease
Lang K. S., Recher M., Junt T., Navarini A. A., Harris N. L., Freigang S., Odermatt B., Conrad C., Ittner L. M., Bauer S. et al., 2005/02. Nature Medicine, 11 (2) pp. 138-45.
[DOI][WoS][Pmid][serval:BIB_A4C1D51E17FF]
 
CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype.
Urosevic M., Conrad C., Kamarashev J., Asagoe K., Cozzio A., Burg G., Dummer R., 2005. Human Pathology, 36 (9) pp. 1020-1024.
[DOI][WoS][Pmid][serval:BIB_66B8526933F1]
 
Dendritic-cell-based therapeutic vaccination against cancer.
Nestle F.O., Farkas A., Conrad C., 2005. Current Opinion in Immunology, 17 (2) pp. 163-169.
[DOI][WoS][Pmid][serval:BIB_1356634020D0]
 
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M., Dummer R., Conrad C., Beyeler M., Laine E., Burg G., Gilliet M., 2005. Journal of the National Cancer Institute, 97 (15) pp. 1143-1153.
[DOI][WoS][Pmid][serval:BIB_AD1793ACCFDE]
 
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.
Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., Burg G., Liu Y.J., Gilliet M., 2005. Journal of Experimental Medicine, 202 (1) pp. 135-143.
[DOI][WoS][Pmid][serval:BIB_BCCB3F25360E]
 
Pyoderma gangrenosum.
Conrad C., Trüeb R.M., 2005. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology, 3 (5) pp. 334-342.
[Pmid][serval:BIB_CF6FE57399D1]
2004
 
The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis.
Nestle F.O., Conrad C., 2004/12. The Journal of investigative dermatology, 123 (6) pp. xiv-xv. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9E5F2A567ED7]
 
Dendritic cell therapy for skin cancer.
Nestle F.O., Conrad C., 2004. Vox Sanguinis, 87 Suppl 2 pp. 112-114.
[DOI][Pmid][serval:BIB_7C743A1FCE66]
 
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
Gilliet M., Conrad C., Geiges M., Cozzio A., Thürlimann W., Burg G., Nestle F.O., Dummer R., 2004. Archives of Dermatology, 140 (12) pp. 1490-1495.
[DOI][WoS][Pmid][serval:BIB_E9FD87CF4E27]
 
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.
Boyman O., Hefti H.P., Conrad C., Nickoloff B.J., Suter M., Nestle F.O., 2004. Journal of Experimental Medicine, 199 (5) pp. 731-736.
[DOI][WoS][Pmid][serval:BIB_AA0D689A3BBB]
2003
 
Dendritic cell-based cancer therapy.
Conrad C., Nestle F.O., 2003/08. Current opinion in molecular therapeutics, 5 (4) pp. 405-412. Peer-reviewed.
[WoS][Pmid][serval:BIB_48A211FC8F8C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University